Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical NK-cell Infusion in Poor Prognosis AML
NCT01947322Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2011
- Primary completion
- Jan 2016
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of haploidentical natural killer cells in acute myeloid leukemia (AML), sponsored by Assistance publique - Hôpitaux de Paris. Started May 2011; status: completed.
02
Drugs
haploidentical natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01947322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01947322.